Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 2, 2011, Pages 184-190

  Iversen, P ^a   Karup, C ^b   Van Der Meulen, E ^b   Tanko L B ^b   Huhtaniemi, I ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Ferring Pharmaceuticals AS   (Denmark)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

degarelix; hot flushes; leuprolide; modifiable risk factors; testosterone

Indexed keywords

DEGARELIX; LEUPRORELIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; HEART RATE; HOT FLUSH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SELF REPORT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BODY WEIGHT; FLUSHING; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HEART RATE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RISK FACTORS; SELF REPORT; TREATMENT OUTCOME;

EID: 79956132880     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.11     Document Type: Article

References (27)

1. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008; 9: 211-228 (Pubitemid 351233730)
2. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287-295 (Pubitemid 40128250)
3. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 1001-1006
4. Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 and 10.8 mg: results of a randomized open-label trial. Urology 2004; 64: 1177-1181 (Pubitemid 39647062)
5. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Kold Olesen T. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-1992
6. Van Poppel H, Tombal B, de la Rosette JJ, Persson B-E, Jensen J-K, Kold Olesen T. Degarelix: a novel gonadotropinreleasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-815
7. Spetz AC, Zetterlund E-L, Varenhorst E, Hammar M. Incidence and management of hot flashes in prostate cancer. J Support Oncol 2003; 1: 263-273
8. Alekshun TJ, Patterson SG. Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy. Supportive Cancer Ther 2006; 4: 30-37
9. Kouriefs C, Georgiou M, Ravi R. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int 2002; 89: 379-383 (Pubitemid 34304362)
10. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244 (Pubitemid 41043794)
11. Chen AC, Petrylak DP. Complications of androgen-deprivation therapy. Curr Urol Rep 2005; 6: 210-216
12. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004; 14: 177-183 (Pubitemid 38582317)
13. Karling P, Hammar M, Varenhorst E. Prevalence and duration of vasomotor symptoms after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170-1173 (Pubitemid 24283460)
14. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Abarelix Study Group et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-1674 (Pubitemid 34240698)
15. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Abarelix Study Group et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-761
16. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006; 2: 677-696 (Pubitemid 44941986)
17. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-1538
18. Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010; 17: 5063-5070
19. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash/ flush studies. J Clin Oncol 2001; 19: 4280-4290 (Pubitemid 33096775)
20. Quella S, Loprinzi CL, Dosee AM. A qualitative approach to defining hot flash/flushes in men. Urol Nurs 1994; 14: 155-158
21. Appling S, Paez K, Allen J. Ethnicity and vasomotor symptoms in postmenopausal women. J Womens Health (Larchmt) 2007; 16: 1130-1138 (Pubitemid 47587337)
22. Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond Engl) 2009; 5: 127-133
23. Thurston RC, Sowers MR, Chang Y, Sternfeld B, Gold EB, Johnston JM et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women0s health across the nation. Am J Epidemiol 2008; 167: 78-85
24. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW et al. European Male Aging Study Group. Hypothalamic-pituitarytesticular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-2745 (Pubitemid 352008544)
25. Badawy A, State O, Sherief S. Can thyroid dysfunction explicate severe menopausal symptoms? J Obstet Gynaecol 2007; 27: 503-505 (Pubitemid 47295319)
26. Pearce EN. Thyroid dysfunction in perimenopausal and postmenopausal women. Menopause Int 2007; 13: 8-13 (Pubitemid 46692063)
27. Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002; 41: 69-77 (Pubitemid 34102391)